Drug Trial Radar · NCT06858397
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 14, 2025
Primary completion
Aug 30, 2028
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- Collaborators
- Hanmi Pharmaceutical Company Limited
- First posted
- Mar 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
Conditions
- Fabry Disesase
Interventions
HM15421/GC1134ADrug
SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences and characteristics of adverse eventsTime frame: Up to 48 weeks
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
David Geffen School of Medicine UCLA, UCLA Health
Los Angeles, California · Recruiting
University of Kansas School of Medicine
Kansas City, Kansas · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
University of Pittsburgh Medical Center Children's Hoispital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Lysosomal and Rare Disorders Research and Treatment Center
Fairfax, Virginia · Recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina · Recruiting
Centro Medico IPAM
Rosario, Santa Fe Province, Argentina · Recruiting
Yonsei University, College of Medicine
Seoul, South Korea · Recruiting
Pusan National University Children's Hospital in Yangsan
Yangsan, Gyeongsangnam-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.